Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1588-1596

  Daniel, R A ^a   Rozanska, A L ^a   Mulligan, E A ^a   Drew, Y ^a   Thomas, H D ^a   Castelbuono, D J ^a   Hostomsky, Z ^b   Plummer, E R ^a   Tweddle, D A ^a   Boddy, A V ^a   Clifford, S C ^a   Curtin, N J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Pf Izer Oncology Inc   (United States)

Author keywords

CNS; medulloblastoma; PARP; temozolomide; xenograft

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; MISMATCH REPAIR; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DACARBAZINE; DNA MISMATCH REPAIR; DNA REPAIR; HUMANS; INDOLES; MEDULLOBLASTOMA; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 78149469318     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605946     Document Type: Article

References (33)

1. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ (2009) Vasoactivity ofAG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentia-tion in vivo? Clin Cancer Res 15: 6106-6112
2. Barone G, Maurizi P, Tamburrinin G, Riccardi R (2006) Role of temozolomide in paediatric brain tumours. Childs Nerv Syst 22: 652-661
3. Baruchel S, Diezia M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42: 2335-2342
4. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A, for the Pediatric Brain Tumor Consortium. (2007) Phase I trial of single-dosetemozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13: 6712-6718
5. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, North M, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang L-Z, Webber SE, Williams KJ, Curtin NJ (2004) Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 96: 56-67
6. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS (2005) Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4: 1364-1368
7. Curtin NJ (2007) Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin Therap Targets 11: 783-799
8. Curtin NJ, Wang L-Z, Yiakouvaki A, Kyle S, Arris CE, Canan-Koch S, Webber SE, Durkacz BW, Calvert AH, Newell DR, Hostomsky Z (2004) Novel PARP-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair deficient cells. Clin Cancer Res 10: 881-889
9. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC (2009) Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 15: 1241-1249
10. Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment and Trojan horses. Clin Can Res 13: 1663-1674
11. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in pre-clinical tumour models. Clin Can Res 13: 2728-2737
12. Fong PC, Bass DS, Yap TA, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2009) Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med 361: 123-134
13. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold Jr SC (1995) Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857
14. Hattori K, Kido Y, Yamamoto H, Ishida J, Iwashita A, Mihara K (2004) Rational approaches to discovery of orally active and brain-penetrable quinazoline inhibitors of poly(ADP-ribose) polymerase. J Med Chem 47: 4151-4154
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003
16. Jagtap P, Szabo C (2005) Poly(ADP-ribose) polymerase and the therapeutic potential of its inhibitors. Nat Rev Drug Disc 4: 421-440
17. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, Grundy RG, Ellison DW, Clifford SC (2006) Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 45: 47-60
18. Lindsey JC, Anderton JA, Lusher ME, Clifford SC (2005) Epigenetic events in medulloblastoma development. Neurosurg Focus 19: E10
19. Macdonald DR (2001) Temozolomide for recurrent high-grade glioma. Semin Oncol 28: 3-12
20. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6: 998-1007
21. Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: temozolo-mide and glioblastoma - look to the future. Nat Clin Pract Oncol 5: 476-486
22. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 110: 1542-1550
23. Pizer B, Clifford S (2008) Medulloblastoma: new insights into biology and treatment. Arch Dis Child Educ Pract Ed 93: 137-144
24. Pizer B, Clifford SC (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 23: 364-375
25. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison G, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes ATase and PARP-1. Clin Cancer Res 11: 3402-3409
26. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H (2008) Phase I sStudy of the poly(ADP-Ribose) polymerase inhibitor, AG-014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923
27. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji R, Calvert H (2006) First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG-014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006 ASCO Annual Meeting Proceedings 2006. Part I 24(18S): 8013
28. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69: 120-127
29. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9: 5370-5379
30. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang L-Z, Webber SE, Curtin NJ (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase (PARP) inhibitor for clinical trial. Mol Cancer Ther 6: 945-956
31. Van Den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, Van Der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528
32. Viana-Pereira M, Almeida I, Sousa S, Mahler-Araújo B, Seruca R, Pimentel J, Reis RM (2009) Analysis of microsatellite instability in medulloblas-toma. Neuro Oncol 11: 458-467
33. Wang CH, Hsu TR, Wong TT, Chang KP (2009) Efficacy of temozolomide for recurrent embryonal brain tumours in children. Childs Nerv Syst 25: 535-541